1-20 of 23669
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The clot thickens: transverse cables under high shear flow

Open Access
Yevgeniy Kreinin, Netanel Korin
Journal: Blood Advances
Blood Adv (2025) 9 (23): 6040–6041.
https://doi.org/10.1182/bloodadvances.2025018019
Published: 2025
Journal Articles

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study

Open Access
Clinical Trials & Observations
Nirav N. Shah, Pier Luigi Zinzani, Michael Wang, Sunita D. Nasta, Ewa Lech-Maranda, Yoshiaki Ogawa, Bita Fakhri, Bryone Kuss, Kaname Miyashita, Krish Patel, Catherine C. Coombs, Shuo Ma, Manish R. Patel, Minal A. Barve, Benoit Tessoulin, Anastasios Stathis, Daisuke Ennishi, Daigo Hashimoto, Kensuke Kojima, Andrew D. Zelenetz, Jonathon B. Cohen, Julie M. Vose, Kami J. Maddocks, Talha Munir, Fangfang Sun, Yuanyuan Bian, Minna Balbas, Donald E. Tsai, Paolo Abada, Chan Y. Cheah
Journal: Blood Advances
Blood Adv (2025) 9 (23): 5954–5964.
https://doi.org/10.1182/bloodadvances.2024014975
Published: 2025
Includes: Supplemental data
Journal Articles

Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide

Open Access
Thomas Systchenko, Laly Nsiala, Arthur Bobin, Hélène Gardeney, Carine Motard, Gaelle Olivier, Florence Borde, Anne Corby, Christophe Roul, Emmanuel Fleck, Guillaume Denis, Céline Dieval, Philippe Mottaz, Annick Boscagli, Gautier Defossez, Xavier Leleu
Journal: Blood Advances
Blood Adv (2025) 9 (23): 6001–6008.
https://doi.org/10.1182/bloodadvances.2025016625
Published: 2025
Includes: Supplemental data
Journal Articles

Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations

Open Access
Navid Djassemi, Benjamin Hanisch, Cecilia Motta, Naseem Maghzian, Anant Vatsayan, Jessica R. Durkee-Shock, Michael D. Keller
Journal: Blood Advances
Blood Adv (2025) 9 (23): 5965–5975.
https://doi.org/10.1182/bloodadvances.2024013727
Published: 2025
Includes: Supplemental data
Journal Articles

Progressive silent cerebral infarction is associated with stroke and persistent cognitive impairment in survivors of iTTP

Open Access
Clinical Trials & Observations
Jia Yu, Jenna Brown, Jay Meade, Gloria F. Gerber, Michael B. Streiff, Peggy Kraus, Samuel Merrill, Allyson M. Pishko, Jennifer Yui, Rakhi P. Naik, Robert A. Brodsky, Doris D. Lin, Shruti Chaturvedi
Journal: Blood Advances
Blood Adv (2025) 9 (23): 5945–5953.
https://doi.org/10.1182/bloodadvances.2025017274
Published: 2025
Journal Articles

Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia

Open Access
Gliceida M. Galarza Fortuna, Lauren Peres, Elena Nazarenko, Andre De Menezes Silva Corraes, Vanna N. Hovanky, Leyla Shune, Joseph McGuirk, Gabriel De Avilla, Jack Khouri, Danai Dima, Mahmoud Gaballa, Binod Dhakal, Peter Forsberg, Amandeep Godara, Aimaz Afrough, Larry Anderson, Megan M. Herr, James A. Davis, Hashim Mann, Sneha Purvey, William Clark, Myo Htut, Amer Beitinjaneh, Denise L. Pereira, Mehmet H. Kocoglu, Christopher James Ferreri, Shebli Atrash, Peter M. Voorhees, Adriana Rossi, Richard Shambavi, Hamza Hashmi, Krina Patel, Surbhi Sidana, Yi Lin, Doris K. Hansen, Douglas W. Sborov
Journal: Blood Advances
Blood Adv (2025) 9 (23): 6009–6018.
https://doi.org/10.1182/bloodadvances.2025016966
Published: 2025
Includes: Supplemental data
Journal Articles

Cardiovascular degeneration in Erdheim-Chester disease: prevalence, burden, and outcomes

Open Access
Reema K. Tawfiq, Grant M. Spears, Jason R. Young, Madeline K. Mahowald, W. Oliver Tobin, Ubenthira Patgunarajah, Gordon J. Ruan, Dongni Yi, Saurabh Zanwar, Karen Rech, Matthew J. Koster, Aldo A. Acosta-Medina, Lucinda Gruber, Aishwarya Ravindran, Mithun Vinod Shah, N. Nora Bennani, Muhamad Alhaj Moustafa, Talal Hilal, Julio C. Sartori Valinotti, Robert Vassallo, Jay H. Ryu, Caroline Davidge-Pitts, Surendra Dasari, Thomas E. Witzig, Ronald S. Go, Gaurav Goyal, Jithma P. Abeykoon
Journal: Blood Advances
Blood Adv (2025) 9 (23): 5988–6000.
https://doi.org/10.1182/bloodadvances.2025016608
Published: 2025
Includes: Supplemental data
Journal Articles

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30 + peripheral T-cell lymphoma

Open Access
Clinical Trials & Observations
Swaminathan Iyer, Neha Mehta-Shah, Ranjana Advani, Nancy L. Bartlett, Jacob H. Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Onder Alpdogan, Tatyana A. Feldman, Vincent Camus, Giuseppe Gritti, Pier Luigi Zinzani, David Belada, Jiri Mayer, Ilseung Choi, June-Won Cheong, Evelyn Rustia, Keenan Fenton, Michelle Fanale, Kerry J. Savage, Steven M. Horwitz
Journal: Blood Advances
Blood Adv (2025) 9 (23): 5976–5987.
https://doi.org/10.1182/bloodadvances.2024015282
Published: 2025
Includes: Supplemental data
Journal Articles

Arterial human blood flow can be stopped by cables of VWF and platelets without coagulation

Open Access
Edouard L. V. Machenaud, John W. Weisel, Rustem I. Litvinov, Chandrasekaran Nagaswami, David N. Ku
Journal: Blood Advances
Blood Adv (2025) 9 (23): 6019–6030.
https://doi.org/10.1182/bloodadvances.2025017354
Published: 2025
Includes: Supplemental data
Journal Articles

Biological parenthood rates among men with sickle cell disease

Open Access
Anyssa N. Young, Sarah R. Hayford, Sapuni S. Chandrasena, Sara Conroy, Tanvi P. Karkare, Barbara L. Kroner, Allison King, Robert M. Cronin, Luca Badolato, Leena Nahata, Susan E. Creary
Journal: Blood Advances
Blood Adv (2025) 9 (23): 6059–6062.
https://doi.org/10.1182/bloodadvances.2025017458
Published: 2025
Journal Articles

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML

Open Access
Clinical Trials & Observations
Swati Naik, Richard Aplenc, Susanne H.C. Baumeister, Marco Becilli, Anand S. Bhagwat, Challice L. Bonifant, Lihua E. Budde, Christopher D. Chien, Kevin J. Curran, Anthony F. Daniyan, Alexandra Dreyzin, Rebecca A. Gardner, Sara Ghorashian, Stephen Gottschalk, LaQuisa C. Hill, M. Eric Kohler, Adam Lamble, Franco Locatelli, Maksim Mamonkin, Bilal Omer, Jae H. Park, Concetta Quintarelli, Benedetta Rambaldi, Rebecca M. Richards, David A. Sallman, Tim Sauer, Nirali N. Shah, Marion Subklewe, Corinne Summers, Sarah K. Tasian, Naomi Taylor, Sarah Tettamanti, Michael R. Verneris, M. Paulina Velasquez, Saar I. Gill
Journal: Blood Advances
Blood Adv (2025) 9 (23): 6047–6058.
https://doi.org/10.1182/bloodadvances.2025017011
Published: 2025
Includes: Supplemental data
Journal Articles

Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series

Open Access
Ellinor Goergen, Sandra Robrecht, Rudy Ligtvoet, Kirsten Fischer, Barbara Eichhorst, Petra Langerbeins, Michael Hallek
Journal: Blood Advances
Blood Adv (2025) 9 (23): 6042–6046.
https://doi.org/10.1182/bloodadvances.2025017109
Published: 2025
Journal Articles

Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF

Open Access
Clinical Trials & Observations
Nicoletta C. Machin, Maria M. Brooks, Deborah Vehec, Dana Ivanco, Brandon Lawryk, Craig D. Seaman, Frederico Xavier, Sruti Shiva, Angela Verdoni, Margaret V. Ragni
Journal: Blood Advances
Blood Adv (2025) 9 (23): 6031–6039.
https://doi.org/10.1182/bloodadvances.2025017046
Published: 2025
Includes: Supplemental data
Journal Articles

Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia

Open Access
Antonio José Cabrera-Serrano, José Manuel Sánchez-Maldonado, Juan José Rodríguez-Sevilla, Fernando Jesús Reyes-Zurita, Rosa Collado, Anna Puiggros, Elena Cornejo-Calvo, Paloma García-Martín, Rob Ter Horst, Yolanda Benavente, Andrés Jerez, Stefano Landi, Blanca Espinet, Rossana Maffei, Miguel Ángel López-Nevot, Silvia Ramos-Campoy, Carmen González-Olmedo, Tzu-Hua Chen-Liang, Víctor Moreno, Fatin Jannus, Rafael Marcos-Gragera, María Carretero-Fernández, Belém Sampaio-Marques, Irene Gámez, María García-Álvarez, Nicola J. Camp, Trinidad Dierssen-Sotos, Joanna Kamaso, Eva María Pérez, Aaron D. Norman, Mario Luppi, Yang Li, Miguel Alcoceba, Daniele Campa, Silvia de San José, Roberto Marasca, Paula Ludovico, Alyssa Clay-Gilmour, Federico Canzian, Marian Ibañez, Mihai G. Netea, James McKay, Delphine Casabonne, Sonja I. Berndt, Susan L. Slager, Juan Sainz
Journal: Blood Advances
Blood Adv (2025) 9 (23): 6076–6089.
https://doi.org/10.1182/bloodadvances.2025017345
Published: 2025
Includes: Supplemental data
Journal Articles

Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis

Open Access
Clinical Trials & Observations
Herman van Besien, Neela Easwar, Michelle Demetres, Michelle Pasciolla, Tsiporah Shore, John Leonard, Juliet Barker, Peter Martin, Samuel Yamshon
Journal: Blood Advances
Blood Adv (2025) 9 (23): 6063–6075.
https://doi.org/10.1182/bloodadvances.2025016291
Published: 2025
Includes: Supplemental data
Images
Shear-dependent assembly of a transverse VWF–platelet cable in a stenosed microchannel. (A) Schematic illustrating left-to-right flow through a stenotic channel mimicking an artery, with associated high-shear thrombi. Channel walls are color-mapped by wall shear stress (blue, low; red, high), with peaks and steep gradients at the constriction slopes and throat. At the upstream edge, a large transverse occlusive mass spans the entire cross-section, composed of parallel platelet strings joined by VWF fiber “yarns.” (B) Schematic showing 2 platelet aggregates (orange), at the stenosis entrance, bridged by dense bundles of ULVWF fibers. These fibers form a high surface-area scaffold that tethers platelets and connects aggregates into a continuous transverse cable, resisting hydrodynamic drag and promoting luminal occlusion under high shear.

Shear-dependent assembly of a transverse VWF–platelet cable in a stenosed m...

Open Access
in The clot thickens: transverse cables under high shear flow > Blood Advances
Published: 2025
Shear-dependent assembly of a transverse VWF–platelet cable in a stenosed microchannel. (A) Schematic illustrating left-to-right flow through a stenotic channel mimicking an artery, with associated high-shear thrombi. Channel walls are color-mapped by wall shear stress (blue, low; red, high), with p... More about this image found in Shear-dependent assembly of a transverse VWF–platelet cable in a stenosed m...
Images
Pirtobrutinib efficacy in patients with R/R FL. Best change in sum of product diameters from baseline. Data for 4 patients are not shown in the waterfall plot due to no measurable target lesions identified by computed tomography scan at baseline, discontinuation before first response assessment, or lack of adequate imaging in follow-up. Data cutoff of 27 January 2025. ∗Indicates patient with a >100% increase in sum of products of diameter, with the corresponding change from baseline of 145.1.

Pirtobrutinib efficacy in patients with R/R FL. Best change in sum of prod...

Open Access
in Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study > Blood Advances
Published: 2025
Figure 1. Pirtobrutinib efficacy in patients with R/R FL. Best change in sum of product diameters from baseline. Data for 4 patients are not shown in the waterfall plot due to no measurable target lesions identified by computed tomography scan at baseline, discontinuation before first response a... More about this image found in Pirtobrutinib efficacy in patients with R/R FL. Best change in sum of prod...
Images
DoR, PFS, and OS among patients with R/R FL. Kaplan-Meier curves describing the investigator-assessed DoR (A) and PFS (B) per Lugano 2014 criteria, and OS (C) of all patients with R/R FL enrolled in the BRUIN study. Patients who were alive and without documented progressive disease (DoR, PFS) as of the data analysis cutoff date were censored. Patients who were alive or lost to follow-up (OS) as of the data analysis cutoff date were censored. Data cutoff of 27 January 2025. NE, not estimable.

DoR, PFS, and OS among patients with R/R FL. Kaplan-Meier curves describin...

Open Access
in Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study > Blood Advances
Published: 2025
Figure 2. DoR, PFS, and OS among patients with R/R FL. Kaplan-Meier curves describing the investigator-assessed DoR (A) and PFS (B) per Lugano 2014 criteria, and OS (C) of all patients with R/R FL enrolled in the BRUIN study. Patients who were alive and without documented progressive disease (Do... More about this image found in DoR, PFS, and OS among patients with R/R FL. Kaplan-Meier curves describin...
Images
DoR by best overall response. Kaplan-Meier curve of investigator-assessed DoR per Lugano 2014 criteria for patients with R/R FL. Patients with CR or PR from first response. NE, not estimable.

DoR by best overall response. Kaplan-Meier curve of investigator-assessed ...

Open Access
in Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study > Blood Advances
Published: 2025
Figure 4. DoR by best overall response. Kaplan-Meier curve of investigator-assessed DoR per Lugano 2014 criteria for patients with R/R FL. Patients with CR or PR from first response. NE, not estimable. More about this image found in DoR by best overall response. Kaplan-Meier curve of investigator-assessed ...
Images
PFS by response status to most recent previous therapy. PFS by response status to most recent previous therapy. Data cutoff of 27 January 2025. NE, not estimable.

PFS by response status to most recent previous therapy. PFS by response st...

Open Access
in Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study > Blood Advances
Published: 2025
Figure 5. PFS by response status to most recent previous therapy. PFS by response status to most recent previous therapy. Data cutoff of 27 January 2025. NE, not estimable. More about this image found in PFS by response status to most recent previous therapy. PFS by response st...